Navigation Links
Exenatide Once Monthly Showed Positive Results in Phase 2 Study
Date:3/10/2011

emic control," said Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals. "Based on the encouraging results of this study, we plan to proceed with regulatory interactions to outline the next steps for this important program."

More than 90 percent of patients overall completed the study. The most common adverse events among the exenatide once monthly treatment groups were headache and nausea. Headache and diarrhea were most common among the once-weekly BYDUREON group. No major or minor hypoglycemia was reported in the study.

Exenatide once monthly is a new, extended-release formulation of exenatide, the active ingredient in BYETTA® (exenatide) injection, which is given twice daily. Exenatide once monthly is based on the same Medisorb® microsphere technology used in BYDUREON.

Study Design

This phase 2, randomized, open-label study included 121 adults with type 2 diabetes who were not achieving adequate glucose control using diet and exercise alone or with a stable regimen of metformin, Actos® (pioglitazone), or both.  Subjects were randomized to receive either 2 mg weekly subcutaneous injections of BYDUREON or subcutaneous injections of exenatide once monthly at a low, medium or high dose, each administered once every four weeks, for a total of 20 weeks.

About Diabetes

Diabetes affects nearly 26 million people in the U.S. and an estimated 285 million adults worldwide.(i, ii)  Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes costs approximately $174 billion per year in direct and indirect medical expenses.(iii)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
3. Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
4. Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
5. New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
6. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
7. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
8. Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
9. BioProcess International Launches Monthly Asia-Pacific eNewsletter
10. Technology PR Boutique Launches PRTechConnect to Help Tech Startups Restart Economy with Industry's First $999 Monthly Service
11. RSB Spine, LLC, Announces Record Second-Quarter 2010 Revenue and Monthly Sales Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
(Date:12/24/2014)... 2014 The report provides basic ... classification, application and industry overview. This report also ... structure. Production is separated by regions, technology and ... equipment, downstream client survey, marketing channels, industry development ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... at the Cambridge University have discovered that freshwater algae ... each other, miraculously held together only by the fluid ... today in the journal Physical Review Letters . ... consists of approximately 1,000 cells arranged on the surface ...
... Kendle (Nasdaq: KNDL ), a leading, global ... not meet analyst expectations for the first quarter of ... unprecedented biopharmaceutical industry conditions, which are resulting in longer ... fewer new requests for proposals and an increase in ...
... --BRISBANE, Calif., April 20 InterMune, Inc. (Nasdaq: ... host a live webcast of a discussion of the INFORM-1 ... at 7:00 p.m. CEST (1:00 p.m. EDT). Participating in ... the INFORM-1 trial. Members of management from Roche, InterMune ...
Cached Biology Technology:Scientists discover 'dancing' algae 2Kendle to Host Conference Call to Discuss Revised 2009 Outlook 2Kendle to Host Conference Call to Discuss Revised 2009 Outlook 3InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25 2
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... CAMBRIDGE, Mass. (April 2, 2009) Whitehead Institute researchers have ... have further clarified the role prions play in the inheritance ... in the field is are the prions functional are ... disease, as in "mad cow," disease in mammals," says Randal ...
... Since the days of Charles Darwin, researchers are interested ... the development of animal and plant species during their ... has already come quite a long way. But there ... animal groups that made their apparation very early in ...
... directly affect human survival and food security, especially as ... groups of social insects to cultivate crops, have harvested ... 50 million years. New results from the Smithsonian show ... combat fungi coming into the nest inside leaves, thus ...
Cached Biology News:Redefining what it means to be a prion 2Redefining what it means to be a prion 3Early family ties: No sponge in the human family tree 2Early family ties: No sponge in the human family tree 3Food security for leaf-cutting ants: Workers and their fungus garden reject endophyte invaders 2
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
Goat anti-mouse gamma chain-HRP...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
Biology Products: